Trials / Completed
CompletedNCT03788746
Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma
A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 181 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the prevalence of pre-treatment tumor tissue PD-L1 expression in patients diagnosed with advanced urothelial carcinoma.
Detailed description
Advanced urothelial carcinoma (UC) (locally advanced/unresectable or metastatic UC) is a fatal disease with 5-year survival rate of 5%. The most frequently studied diagnostic for advanced UC is the programmed death-ligand 1 (PD-L1) protein expression in tumor tissue. A better understanding of PD-L1 expression in a "real world" setting could help understand its clinical utility in the management and decision making in advanced UC and clinical trial design
Conditions
Timeline
- Start date
- 2019-01-17
- Primary completion
- 2022-01-12
- Completion
- 2023-05-25
- First posted
- 2018-12-28
- Last updated
- 2024-02-22
Locations
58 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03788746. Inclusion in this directory is not an endorsement.